Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

153 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Skin dendritic cells in melanoma are key for successful checkpoint blockade therapy.
Prokopi A, Tripp CH, Tummers B, Hornsteiner F, Spoeck S, Crawford JC, Clements DR, Efremova M, Hutter K, Bellmann L, Cappellano G, Cadilha BL, Kobold S, Boon L, Ortner D, Trajanoski Z, Chen S, de Gruijl TD, Idoyaga J, Green DR, Stoitzner P. Prokopi A, et al. Among authors: kobold s. J Immunother Cancer. 2021 Jan;9(1):e000832. doi: 10.1136/jitc-2020-000832. J Immunother Cancer. 2021. PMID: 33408092 Free PMC article.
Strategies to relieve immunosuppression in pancreatic cancer.
Schnurr M, Duewell P, Bauer C, Rothenfusser S, Lauber K, Endres S, Kobold S. Schnurr M, et al. Among authors: kobold s. Immunotherapy. 2015;7(4):363-76. doi: 10.2217/imt.15.9. Immunotherapy. 2015. PMID: 25917628 Review.
Using Antigen-Specific B Cells to Combine Antibody and T Cell-Based Cancer Immunotherapy.
Wennhold K, Thelen M, Schlößer HA, Haustein N, Reuter S, Garcia-Marquez M, Lechner A, Kobold S, Rataj F, Utermöhlen O, Chakupurakal G, Theurich S, Hallek M, Abken H, Shimabukuro-Vornhagen A, von Bergwelt-Baildon M. Wennhold K, et al. Among authors: kobold s. Cancer Immunol Res. 2017 Sep;5(9):730-743. doi: 10.1158/2326-6066.CIR-16-0236. Epub 2017 Aug 4. Cancer Immunol Res. 2017. PMID: 28778961
High-affinity CD16-polymorphism and Fc-engineered antibodies enable activity of CD16-chimeric antigen receptor-modified T cells for cancer therapy.
Rataj F, Jacobi SJ, Stoiber S, Asang F, Ogonek J, Tokarew N, Cadilha BL, van Puijenbroek E, Heise C, Duewell P, Endres S, Klein C, Kobold S. Rataj F, et al. Among authors: kobold s. Br J Cancer. 2019 Jan;120(1):79-87. doi: 10.1038/s41416-018-0341-1. Epub 2018 Nov 15. Br J Cancer. 2019. PMID: 30429531 Free PMC article.
Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells.
Benmebarek MR, Karches CH, Cadilha BL, Lesch S, Endres S, Kobold S. Benmebarek MR, et al. Among authors: kobold s. Int J Mol Sci. 2019 Mar 14;20(6):1283. doi: 10.3390/ijms20061283. Int J Mol Sci. 2019. PMID: 30875739 Free PMC article. Review.
153 results